Seagen Inc (OQ:SGEN)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: 21823 30th Dr SE
BOTHELL WA 98021-3907
Tel: N/A
IR: See website
Key People
Clay B. Siegall
Chairman of the Board, President, Chief Executive Officer
Todd E. Simpson
Chief Financial Officer
Jean I. Liu
Executive Vice President - Legal Affairs, General Counsel, Corporate Secretary
Vaughn B. Himes
Chief Technical Officer
Roger D. Dansey
Chief Medical Officer
Business Overview
Seagen Inc., formerly Seattle Genetics, Inc., is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company is commercializing ADCETRIS or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas; PADCEV or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers, and TUKYSA or tucatinib, for treatment of certain metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancers. The Company is also developing a pipeline of therapies for solid tumors and blood-related cancers designed to address unmet medical needs. Its pipeline includes ladiratuzumab vedotin, an antibody-drug conjugate (ADC) targeting LIV-1.
Financial Overview
For the nine months ended 30 September 2020, SeagenInc revenues increased from $626.9M to $1.57B. Net incometotaled $446.6M vs. loss of $184.5M. Revenues reflectRoyalty revenues increase from $66.2M to $809.9M, Netproduct sales increase of 53% to $706.5M. Net Incomereflects Investment and other income (loss), net increasefrom $2.3M (expense) to $18M (income).
Employees: 1,605 as of Dec 31, 2019
Reporting Currency: U.S. Dollars
Enterprise value: $31,774M as of Sep 30, 2020
Annual revenue (TTM): $1,864M as of Sep 30, 2020
EBITDA (TTM): $439.87M as of Sep 30, 2020
Net annual income (TTM): $472.41M as of Sep 30, 2020
Free cash flow (TTM): $570.68M as of Sep 30, 2020
Net Debt Last Fiscal Year: N/A
Shares outstanding: 180,306,390 as of Oct 27, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.